These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25682970)

  • 1. New options in the treatment of autosomal dominant polycystic kidney disease.
    Kazancioglu R; Gursu M
    Ren Fail; 2015 May; 37(4):535-41. PubMed ID: 25682970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?
    Kou P; Wei S; Xiong F
    Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
    Cornec-Le Gall E; Le Meur Y
    Nephrol Ther; 2014 Nov; 10(6):433-40. PubMed ID: 25086476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
    Rysz J; Gluba-Brzózka A; Franczyk B; Banach M; Bartnicki P
    Expert Opin Pharmacother; 2016 Oct; 17(15):2049-56. PubMed ID: 27650472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatments of autosomal dominant polycystic kidney disease.
    Mahnensmith RL
    Clin J Am Soc Nephrol; 2014 May; 9(5):831-6. PubMed ID: 24721886
    [No Abstract]   [Full Text] [Related]  

  • 9. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in autosomal dominant polycystic kidney disease-2014 and beyond.
    Braun WE
    Cleve Clin J Med; 2014 Sep; 81(9):545-56. PubMed ID: 25183846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug therapy for polycystic kidney disease: a review and perspective.
    Aguiari G; Catizone L; Del Senno L
    Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease].
    Joly D
    Med Sci (Paris); 2011 Mar; 27(3):249-51. PubMed ID: 21447293
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis.
    Lin CH; Chao CT; Wu MY; Lo WC; Lin TC; Wu MS
    Int Urol Nephrol; 2019 Nov; 51(11):2015-2025. PubMed ID: 31578673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modern treatment of autosomal dominant polycystic kidney disease].
    Wołyniec W; Jankowska MM; Rutkowski B
    Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapies for ADPKD].
    Rathaus M
    G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
    N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
    Ponticelli C; Locatelli F
    Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
    [No Abstract]   [Full Text] [Related]  

  • 20. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy.
    Wüthrich RP; Serra AL; Kistler AD
    Kidney Blood Press Res; 2009; 32(5):380-7. PubMed ID: 19887826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.